Tests nicorandil given into heart arteries to prevent reduced blood flow during stenting
Tests nicorandil injected into heart arteries before stenting in people with coronary artery disease.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 4
Where in South Korea
- Korea University Anam HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Korea University Anam Hospital
- Trial code
- NCT05427786
- Record updated
- 8 September 2026
- Original description
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.Read full original descriptionShow less
A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
The aim of this study was to determine the effect of intra-coronary administration of nicorandil on the prevention of lowering of coronary blood flow for high-risk plaque lesions defined as the high value of lipid core burden index in patients with coronary artery disease who require stent treatment.
Inclusion: Over 19 years old; Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information; Patients who underwent NIRS-IVUS guided coronary stent surgery for coronary artery disease; maxLCBI4mm ≥354 in the culprit lesion measured by NIRS-IVUS.
Exclusion: Subjects who plan to have surgery to stop antiplatelet drugs within 6 months from registration; Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.); Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study; Patients with TIMI ≤ 2 before coronary intervention; Those whose surviving life is expected to be less than 1 year; Subjects who visited the hospital due to cardiogenic shock and are predicted to have low survival probability based on medical judgment.